Bavarian Nordic enters license agreement with Nuance Pharma on RSV candidate

On Monday, Bavarian Nordic announced that a license and supply agreement has been completed with Shanghai-based biotech company Nuance Pharma, regarding the rights for the Danish company’s RSV vaccine candidate, a stock notification reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic expects revenue setback in 2022
For subscribers